Clinical Trial

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-11-20; most recent amendment 2026-05-28.
Status change: Recruiting → Active, Not Recruiting 2025-09-10
Status change: Not Yet Recruiting → Recruiting 2024-02-03
Trial Details
NCT Number NCT06149793
Lead Sponsor University of Minnesota
Conditions Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Enrollment 8 participants
Start Date 2024-01-08
Primary Completion 2025-06-03 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-20